176 related articles for article (PubMed ID: 28987455)
1. In vitro characterization and mouthfeel study of functionalized calcium carbonate in orally disintegrating tablets.
Wagner-Hattler L; Wyss K; Schoelkopf J; Huwyler J; Puchkov M
Int J Pharm; 2017 Dec; 534(1-2):50-59. PubMed ID: 28987455
[TBL] [Abstract][Full Text] [Related]
2. Functionalized calcium carbonate as a novel pharmaceutical excipient for the preparation of orally dispersible tablets.
Stirnimann T; Di Maiuta N; Gerard DE; Alles R; Huwyler J; Puchkov M
Pharm Res; 2013 Jul; 30(7):1915-25. PubMed ID: 23604923
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of novel multi-channel orally disintegrating tablets.
Yu J; Shan X; Chen S; Sun X; Song P; Zhao R; Hu L
Eur J Pharm Sci; 2020 Jan; 142():105108. PubMed ID: 31669391
[TBL] [Abstract][Full Text] [Related]
4. A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate.
Liu Y; Li P; Qian R; Sun T; Fang F; Wang Z; Ke X; Xu B
Drug Dev Ind Pharm; 2018 Aug; 44(8):1317-1327. PubMed ID: 29521132
[TBL] [Abstract][Full Text] [Related]
5. Application of a quality-by-design approach for utilizing sodium stearyl fumarate as a taste-masking agent in dextromethorphan hydrobromide orally disintegrating tablets.
Mahrous GM; Ibrahim MA; Mostafa HF; Elzayat EM
Pharm Dev Technol; 2019 Jul; 24(6):711-719. PubMed ID: 30714850
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex.
Kim JI; Cho SM; Cui JH; Cao QR; Oh E; Lee BJ
Int J Pharm; 2013 Oct; 455(1-2):31-9. PubMed ID: 23933050
[TBL] [Abstract][Full Text] [Related]
7. Compaction of functionalized calcium carbonate, a porous and crystalline microparticulate material with a lamellar surface.
Stirnimann T; Atria S; Schoelkopf J; Gane PA; Alles R; Huwyler J; Puchkov M
Int J Pharm; 2014 May; 466(1-2):266-75. PubMed ID: 24631309
[TBL] [Abstract][Full Text] [Related]
8. Clinical disintegration time of orally disintegrating tablets clinically available in Japan in healthy volunteers.
Yoshita T; Uchida S; Namiki N
Biol Pharm Bull; 2013; 36(9):1488-93. PubMed ID: 23995661
[TBL] [Abstract][Full Text] [Related]
9. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
10. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.
Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA
Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous investigation of the liquid transport and swelling performance during tablet disintegration.
Al-Sharabi M; Markl D; Mudley T; Bawuah P; Karttunen AP; Ridgway C; Gane P; Ketolainen J; Peiponen KE; Rades T; Zeitler JA
Int J Pharm; 2020 Jun; 584():119380. PubMed ID: 32407939
[TBL] [Abstract][Full Text] [Related]
12. PREPARATION AND CHARACTERIZATION OF ORALLY DISINTEGRATING LORATADINE TABLETS MANUFACTURED WITH CO-PROCESSED MIXTURES.
Amelian A; Szekalska M; Wilczewska AZ; Basa A; Winnicka K
Acta Pol Pharm; 2016; 73(2):453-60. PubMed ID: 27180438
[TBL] [Abstract][Full Text] [Related]
13. New advances in the characterization of lyophilised orally disintegrating tablets.
Vanbillemont B; Everaert H; De Beer T
Int J Pharm; 2020 Apr; 579():119153. PubMed ID: 32084575
[TBL] [Abstract][Full Text] [Related]
14. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
Al-Khattawi A; Mohammed AR
Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
[TBL] [Abstract][Full Text] [Related]
15. Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability.
Takano H; Uchida S; Kashiwagura Y; Tanaka S; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N
Chem Pharm Bull (Tokyo); 2019; 67(2):112-119. PubMed ID: 30713270
[TBL] [Abstract][Full Text] [Related]
16. Formulation studies for mirtazapine orally disintegrating tablets.
Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
[TBL] [Abstract][Full Text] [Related]
17. A new formulation for orally disintegrating tablets using a suspension spray-coating method.
Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
Int J Pharm; 2009 Dec; 382(1-2):80-7. PubMed ID: 19686825
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of orally disintegrating tablets comprising taste-masked mirtazapine granules.
Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Vural İ; Ünlü N
Pharm Dev Technol; 2018 Jun; 23(5):488-495. PubMed ID: 28368673
[TBL] [Abstract][Full Text] [Related]
19. Amorphous Formulation and in Vitro Performance Testing of Instantly Disintegrating Buccal Tablets for the Emergency Delivery of Naloxone.
Alqurshi A; Kumar Z; McDonald R; Strang J; Buanz A; Ahmed S; Allen E; Cameron P; Rickard JA; Sandhu V; Holt C; Stansfield R; Taylor D; Forbes B; Royall PG
Mol Pharm; 2016 May; 13(5):1688-98. PubMed ID: 26977787
[TBL] [Abstract][Full Text] [Related]
20. Stability investigation of FCC-based tablets for oral suspension with caffeine and oxantel pamoate as model drugs.
Wagner-Hattler L; Schoelkopf J; Huwyler J; Puchkov M
Drug Dev Ind Pharm; 2019 Feb; 45(2):222-230. PubMed ID: 30260721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
